Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

NCT00877773 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

44

Enrollment

OTHER

Sponsor class

Stopped Slow Accrual

Conditions

Advanced Cancers

Interventions

DRUG: Temsirolimus

Sponsor

M.D. Anderson Cancer Center